Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06183658
Other study ID # YL2023-001
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date May 1, 2021
Est. completion date April 30, 2026

Study information

Verified date December 2023
Source Shenzhen Bay Laboratory
Contact Mengyi Ge, Ph.D.
Phone +8618665351340
Email gemy@szbl.ac.cn
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The goal of this observational study is to learn about the pathophysiology characterization and evolutionary patterns of Alzheimer's disease (AD) in South China older adults. The primary purposes are as follows: 1. The prevalence and characteristics of AD in South China's aging population 2. Identify novel biomarkers and neuroimaging techniques for early detection and intervention of AD 3. Supporting and fertilizing novel approaches and techniques for early diagnosis and intervention of AD Participants will undergo cognitive assessments, blood sample collection, and genetic testing. Some will undergo CSF collection, stool sample collection, MRI scanning, Aβ PET scanning, and tau PET scanning.


Description:

The Greater-Bay-Area Healthy Aging Brain Study (GHABS), a community-based longitudinal cohort study, aimed to characterize of Alzheimer's disease in South China's Aging Population, was launched in May 2021 in Shenzhen. The GHABS project was approved by the Shenzhen Bay Laboratory's and the collaborated hospitals' Ethical Committees. Each participant signed the written informed consent of the GHABS project before enrollment. The participants who met the inclusion and exclusion requirements were informed about the baseline and follow-up examinations. From 2021 to 2026, the GHABS cohort will recruit 1400 individuals aged 55 and older, including 1100 CU older adults, 200 MCI patients, and 100 dementia patients. All the GHABS participants will undergo cognitive assessments, genetic screening, and blood sample collection. Some will have CSF collection, stool sample collection, MRI scanning, Aβ PET scanning, and tau PET scanning. All baseline examinations will be completed within three months. At follow-up, clinical assessments and blood sample collection will be conducted annually. CSF sample collection, MRI scan, Aβ PET scan, and tau PET scan are evaluated every two years.


Recruitment information / eligibility

Status Recruiting
Enrollment 1400
Est. completion date April 30, 2026
Est. primary completion date April 30, 2026
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 55 Years to 90 Years
Eligibility Inclusion Criteria: - This project intends to recruit men and women between the ages of 55 and 90. The inclusion criteria are as listed: - Age 55-90 years old (including 55 and 90 years old). However, people with autosomal dominant and other familial Alzheimer disease (FAD) are not limited by age. - The score of the Geriatric Depression Scale (GDS) is less than 6 points. - There is a caregiver who can maintain at least 10 hours of contact per week and can accompany volunteers to the test site for testing. - Visual and auditory acuity is sufficient for neuropsychological testing. (Including normal corrected vision and hearing) - Be in good health and are expected to be free of disease interference during the study. - Volunteers are not pregnant, lactating or have reproductive potential (that is, women must be two years after menopause or undergo sterilization surgery). - Willingness and ability to participate in longitudinal imaging studies. - A modified version of the Hachinski Ischemic scores less than or equal to 4. - Have completed grade 6 education or have good work experience (sufficient to rule out mental retardation). - Must be able to speak Mandarin fluently. - Willing to undergo multiple 3T MRI scans and at least two PET scans. - Agree to collect blood for genomic analysis (including GWAS sequencing and other analyses), AD risk and protective genes such as apolipoprotein E (APOE), klotho, etc., and biological sample storage. - Agree to collect blood for biomarker detection. - Agree to share genomic data and biomarker samples. Exclusion Criteria: - MRI brain scan screening reveals infection, infarction or other focal lesions or multiple lacunes or lacunes in key memory structures. - Any volunteers who do not meet the MRI scan requirements, including having a cardiac pacemaker, eyes, skin or metal fragments or foreign bodies in the body. - Severe depression, bipolar affective disorder described in DSM-IV in the past year. - Psychotic features, agitation or behavioral problems that may lead to difficulty complying with the protocol content in the past 3 months. - Currently using medication to treat obsessive-compulsive disorder or attention deficit disorder. - History of schizophrenia (meeting DSM-IV criteria). - History of alcohol or drug abuse or dependence within the past 2 years (metting DSM-IV criteria). - Any major systemic disease or unstable physical condition that may make longitudinal research difficult. - Clinically significant abnormalities of B12 or TFTs may interfere with the study, low B12 will be excluded. - Currently using certain psychoactive medications (e.g., certain antidepressants, neuro-depressants, chronic anxiolytics, or sedative-hypnotics). Currently using warfarin or other anticoagulants such as dabigatran, rivaroxaban, and apixaban (except lumbar puncture). - Use of prohibited drugs. - Simultaneously participating in other clinical studies involving neuropsychiatry.

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Fluids biomarker and neuroimaging of AD diagnosis
Early diagnosis of Alzheimer's disease in South China aging population using fluids biomarker and neuroimaging.

Locations

Country Name City State
China Shenzhen Bay Laboratory Shenzhen Other

Sponsors (4)

Lead Sponsor Collaborator
Shenzhen Bay Laboratory Guangdong Basic and Applied Basic Science Foundation, National Natural Science Foundation of China, Shenzhen Science and Technology Innovation Commission

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other Correlation of microbiome to Alzheimer's Disease Correlation of microbiome to Alzheimer's Disease via relative abundance found in gut microbiome study. These data will then be correlated to Alzheimer's disease state 1 time sampling
Primary Longitudinal changes of cognitive function _ ADAS-Cog Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) An average of 1 year
Primary Longitudinal changes of cognitive function _ MMSE, the Chinese version Mini-mental State Examination (MMSE, the Chinese version) An average of 1 year
Primary Longitudinal changes of cognitive function _ MoCA-Basic Montreal Cognitive Assessment Basic (MoCA-Basic) An average of 1 year
Primary Longitudinal functional and behavioral function _ CDR Clinical Dementia Rating (CDR) An average of 1 year
Primary Longitudinal functional and behavioral function _ NPI Neuropsychiatric Inventory (NPI) An average of 1 year
Primary Longitudinal functional and behavioral function _ GDS Geriatric Depression Scale (GDS) An average of 1 year
Primary Longitudinal functional and behavioral function _ FAQ Function Activities Questionnaire (FAQ) An average of 1 year
Primary Longitudinal functional and behavioral function _ ADL Activity of Daily Living Scale (ADL) An average of 1 year
Primary Longitudinal functional and behavioral function _ PSQI Pittsburgh sleep quality index (PSQI) An average of 1 year
Primary Longitudinal functional and behavioral function _ RBDSQ REM sleep behavior disorder screening questionnaire (RBDSQ) An average of 1 year
Secondary Longitudinal changes of plasma biomarkers Longitudinal changes of disease status as categorized by plasma biomarkers of Alzheimer's diseases over time. An average of 1 year
Secondary Longitudinal changes of CSF biomarkers Longitudinal changes of disease status as categorized by CSF biomarkers of Alzheimer's diseases over time. An average of 2 years
Secondary Longitudinal changes in neuroimaging _ MRI images Longitudinal change in brain structure using magnetic resonance imaging (MRI) An average of 2 years
Secondary Longitudinal changes in neuroimaging _ amyloid PET images Longitudinal changes in amyloid deposition An average of 2 years
Secondary Longitudinal changes in neuroimaging _ tau PET images Longitudinal changes in tau deposition An average of 2 years
See also
  Status Clinical Trial Phase
Completed NCT05040048 - Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
Withdrawn NCT03316898 - A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease Phase 1
Withdrawn NCT02860065 - CPC-201 Alzheimer's Disease Type Dementia: PET Study Phase 2
Completed NCT01315639 - New Biomarker for Alzheimer's Disease Diagnostic N/A
Not yet recruiting NCT03740178 - Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005) Phase 1
Recruiting NCT05607615 - A 6-Month Study to Evaluate the Safety & Potential Efficacy of Trappsol Cyclo in Patients With Early Alzheimer's Disease Phase 2
Terminated NCT03307993 - Positron Emission Tomography (PET) Study in Patients With Alzheimer's Disease Phase 1
Recruiting NCT02912936 - A Medium Chain Triglyceride Intervention for Patients With Alzheimer Disease N/A
Active, not recruiting NCT02899091 - Evaluation of the Safety and Potential Therapeutic Effects of CB-AC-02 in Patients With Alzheimer's Disease Phase 1/Phase 2
Not yet recruiting NCT02868905 - Identification of Epigenetic Markers Common to Obesity and Alzheimer's Disease in Women N/A
Completed NCT02907567 - Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease Phase 1/Phase 2
Terminated NCT02521558 - Effectiveness of Home-based Electronic Cognitive Therapy in Alzheimer's Disease N/A
Completed NCT02516046 - 18F-AV-1451 Autopsy Study Phase 3
Completed NCT02580305 - SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study Phase 2
Recruiting NCT02247180 - Cognitive Rehabilitation in Alzheimer`s Disease N/A
Completed NCT02317523 - Alzheimer's Caregiver Coping: Mental and Physical Health N/A
Terminated NCT02220738 - Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors Phase 1
Completed NCT02256306 - The PLasma for Alzheimer SymptoM Amelioration (PLASMA) Study N/A
Completed NCT02260167 - Treatment of Alzheimer's and Dementia With the Metabolism, Infections, Nutrition, Drug Elimination (MIND) Protocol N/A
Completed NCT02089555 - African American Alzheimer's Progression Markers - CSF and Neuro-Imaging N/A